Atreo, Inc., a San Francisco, CA-based Clinical Development SaaS company focused on modernizing and simplifying the clinical trials process, announced that it closed a $4 million Series Seed Preferred financing round, bringing Atreo's total funding to $5.75 million.
The round was led by Jon Dole, Lead Investor & Strategic Advisor executives. Atreo is thrilled to welcome Slack Co-Founders Stewart Butterfield and Cal Henderson to its investor team.
The investment intends to use to accelerate Atreo Growth of the Revolutionary RTSM Platform
Company: Atreo Inc.
Round: Seed Round
Funding Month: Aug 2022
Lead Investors: Jon Dole
Additional Investors: Stewart Butterfield and Cal Henderson
Company Website: https://atreo.io/
Software Category: Randomization and Trial Supply Management (RTSM)
About the Company: Atreo is a clinical technology company comprised of experienced clinical technology experts that have created the next generation of RTSM platforms. Atreo helps clinical teams to modernize the RTSM experience with unmatched agility and simplicity by leveraging advanced technology and testing methods. Atreo has addressed all common RTSM pain points, its mission is to develop the most advanced, agile, and smartest RTSM solution in the market.